Gilead Sciences GILD Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AmBisome | $138M+16.9% | $118M-4.1% | $123M-4.7% | $129M-7.2% | $139M+27.5% | |
| Biktarvy | $3.36B-15.3% | $3.97B+7.7% | $3.69B+4.4% | $3.53B+12.1% | $3.15B-16.5% | |
| Descovy | $807M-1.5% | $819M+16.8% | $701M+7.4% | $653M+11.4% | $586M-5.0% | |
| Genvoya | $264M-30.5% | $380M+0.8% | $377M0.0% | $377M+3.6% | $364M-22.6% | |
| Livdelzi | $133M— | —— | —— | —— | $40M— | |
| Odefsey | $221M-28.7% | $310M+11.9% | $277M-7.0% | $298M+6.0% | $281M-16.4% | |
| Other HIV | $73M-61.6% | $190M+69.6% | $112M+4.7% | $107M+17.6% | $91M-18.8% | |
| Other Liver Disease | $114M-59.4% | $281M+21.6% | $231M+14.9% | $201M+66.1% | $121M-6.9% | |
| Other | $58M-32.6% | $86M+41.0% | $61M-16.4% | $73M+4.3% | $70M-6.7% | |
| Royalty, contract and other revenues | $14M-36.4% | $22M-94.8% | $424M+1,470% | $27M-50.0% | $54M+63.6% | |
| Sofosbuvir/Velpatasvir | $283M+2.5% | $276M-10.7% | $309M-9.6% | $342M-1.2% | $346M+4.8% | |
| Symtuza - Revenue share | $138M+3.8% | $133M+7.3% | $124M0.0% | $124M+8.8% | $114M-20.8% | |
| Tecartus | $75M-16.7% | $90M+8.4% | $83M-9.8% | $92M+17.9% | $78M-20.4% | |
| Trodelvy | $402M+4.7% | $384M+7.6% | $357M-1.9% | $364M+24.2% | $293M-17.5% | |
| Veklury | $144M-31.8% | $211M-23.8% | $277M+129% | $121M-59.9% | $302M-10.7% | |
| Vemlidy | $237M-17.4% | $287M+2.5% | $280M+11.1% | $252M0.0% | $252M-3.1% | |
| Yescarta | $332M-9.8% | $368M+5.4% | $349M-11.2% | $393M+1.8% | $386M-0.8% | |
| Yeztugo | $166M— | —— | —— | —— | $0— | |
| Total revenues by Geography | ||||||
| Europe | $1.14B-7.4% | $1.24B-20.5% | $1.56B+30.8% | $1.19B+9.7% | $1.08B-7.7% | |
| Rest of World | $889M+9.3% | $813M-12.9% | $933M+10.8% | $842M-8.0% | $915M+10.8% | |
| U.S. | $4.93B-16.2% | $5.88B+11.3% | $5.28B+4.6% | $5.05B+8.2% | $4.67B-16.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gilead Sciences break its business down?
- Gilead Sciences (GILD) reports total revenues by product across 18 parts — AmBisome, Biktarvy, Descovy, Genvoya and Livdelzi. Each is extracted from the segment footnotes and tracked over time.
- Where does Gilead Sciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gilead Sciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
